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longed morbidity.2,3
The main treatments are bronchodilators
and systemic corticosteroids. While cortico-
steroids have been shown to be effective,4-7
there is a lack of consensus regarding the
dose, length and route of administration.5
There is considerable variation regarding
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Objective:  To determine whether a 5-day course of oral prednisolone is superior to a 
3-day course in reducing the 2-week morbidity of children with asthma exacerbations 
who are not hospitalised.
Design, setting and participants:  Double-blind randomised controlled trial of asthma 
outcomes following a 5-day course of oral prednisolone (1 mg/kg) compared with a 
 course of prednisolone plus placebo for 2 days. Participants were children aged 
 years who presented to the emergency departments of three Queensland 
itals between March 2004 and February 2007 with an acute exacerbation of asthma, 
ere not hospitalised. Sample size was defined a priori for a study power of 90%.
 outcome measures:  Difference in proportion of children who were symptom-free 
y 7, as measured by intention-to-treat (ITT) and per-protocol analysis; quality of life 
) on Days 7 and 14.
Results:  201 children were enrolled, and there was an 82% completion rate. There was 
no difference between groups in the proportion of children who were symptom-free 
(observed difference, 0.04 [95% CI, − 0.09 to 0.18] by ITT analysis; 0.04 [95% CI, − 0.17 to 
0.09] by per-protocol analysis). There was also no difference between groups in QOL 
(P = 0.42). The difference between groups for the primary outcome was within the 
equivalence range calculated post priori.
Conclusion:  A 5-day course of oral prednisolone confers no advantage over a 
3-day course for children with asthma exacerbations who are not hospitalised.
Trial registration: 
MJA 2008; 189: 306–310
 Australian Clinical Trials Registry ACTRN012605000305628.xa
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tatE cerbation of childhood asthma ise the most common acute presen-ions to general practices and
emergency departments (EDs). Most of
these children are not hospitalised, but
asthma exacerbations are associated with
significant cost1 and both acute and pro-
length of administration among published
guidelines8-10 and systematic reviews,4-6 vary-
ing from 1–3 days to 3–10 days.6 Australian
guidelines recommend oral cortico-steroids
(prednisolone, 1 mg/kg, up to 60 mg daily)
for up to 5 days,8 while United States guide-
lines recommend 1–2 mg/kg/day (in two
doses) for 3–10 days.9
However, few studies have compared the
dose and length of corticosteroid adminis-
tration.5,11 While a longer course of oral
corticosteroids might improve short-term
symptoms of asthma and quality of life
(QOL), adverse events seen in children after
short courses of corticosteroids include
behavioural changes, hallucinations, fungal
infections, increased appetite and adrenal
insufficiency.12,13 Thus, it is desirable to
keep courses of oral corticosteroids as short
as possible while retaining efficacy.
We conducted a double-blind, multi-
centre randomised controlled trial with con-
cealed allocation to compare the efficacy of
a 5-day course versus a 3-day course of oral
prednisolone in reducing the 2-week mor-
bidity of acute asthma exacerbations in
children.
METHODS
Participants were children aged 2–15 years
who presented during ordinary hours
(07:30–17:00) to the EDs of three Queens-
land hospitals (Royal Children’s Hospital
[Brisbane, Qld], Mater Hospital [Brisbane,
Qld] or Gympie Hospital [Gympie, Qld])
with an acute exacerbation of asthma
between March 2004 and February 2007
(however, the start date was different for
each hospital: Royal Children’s Hospital:
March 2004; Mater Hospital: December
2004; Gympie Hospital: July 2006), but
were not hospitalised.
Asthma was defined as recurrent (>2) epi-
sodes of wheeze and/or dyspnoea with a
clinical response (decreased respiratory rate
and work of breathing) to salbutamol. Asthma
exacerbation was defined as acute deteriora-
tion of asthma control requiring treatment
with more than a single dose (> 600μg via
metered dose inhaler and spacer or > 2.5 mg
nebulised) of salbutamol in an hour.
Exclusion criteria were: underlying respi-
ratory disease (eg, bronchiectasis); cerebral
palsy or severe neurodevelopmental abnor-
mality; immunodeficiency; previous enrol-
ment in the study; being on maintenance
oral corticosteroids; having received > 1
dose of oral corticosteroids before presenta-
tion; and very severe asthma (status asth-
mat icus;  requiring hosp i ta l i sa tion,
continuous nebulisation, and/or intravenous
salbutamol).
The study was approved by the human
ethics committees of all three institutions.
The trial was registered with the Australian
Clinical Trials Registry (ACTRN0126
05000305628).
Study protocol
Before discharge from the ED, eligible chil-
dren and their parents or carers were
approached by a study nurse not involved in
the child’s acute treatment. Written
informed consent was obtained from a par-
ent or carer. Children were randomised
within strata of age (< 6 or 6–15 years) and
site of enrolment.
On recruitment, children were allocated
to the next treatment regimen on a list
(randomised by permutated block design
at a remote site). A sticker obscured theA • Volume 189 Number 6 • 15 September 2008
RESEARCHnext treatment group and was only
removed after enrolment (concealed treat-
ment allocation).
Children received either oral pred-
nisolone (1 mg/kg to a maximum of 50 mg/
day; Redipred, Aspen Pharmacare, Sydney,
NSW) for 5 days (“5-day group”) or pred-
nisolone for 3 days, followed by a placebo (a
liquid with a similar taste, also manufac-
tured by Aspen Pharmacare) for 2 days (“3-
day group”).
The trial medications were stored in iden-
tical bottles and labelled A and B. The study
team (other than the pharmacist, who was
not involved in data collection), children and
parents were blinded to the trial medication.
The code was revealed only after the study
and statistical analysis were completed.
Data collection
At recruitment, a clinical history and exami-
nation were undertaken and documented
on a standardised data collection sheet.
Questions specific to asthma (eg, number of
exacerbations in previous 12 months, rou-
tine medications) were asked. Severity of
acute asthma on presentation was catego-
rised according to the Asthma Severity Scale
(ASS) (0–3 = mild;  4 = moderate).14
Scores on the five-point Australasian Triage
Scale (1 = immediately life-threatening; 3 =
potentially life-threatening; 5 = less urgent)
were also recorded.15
Baseline and weekly Paediatric Asthma Car-
egiver’s Quality of Life Questionnaire (PAC-
QLQ) scores16 and validated daily diary
scores for asthma17 and cough18 were
recorded. The asthma score was the average of
four questions.17 Follow-up phone calls
occurred 24–48 hours after enrolment and at
Days 7, 14, 21 and 28, where PACQLQ scores
and adverse events were specifically recorded.
Outcomes
The endpoint was admission into any hospi-
tal or Day 28, whichever occurred first.
However, as a significant number of parents
found it too difficult to complete diaries for
28 days, we analysed data up to Day 14.
Symptoms refer to asthma-specific symp-
toms as recorded in the diary cards.
The primary outcome was the proportion
of children without asthma symptoms, as
scored on the validated diary cards on Day
7. Children were considered still symptom-
atic if their average asthma score for the day
was  0.2.
The main secondary outcomes were PAC-
QLQ scores on Days 7 and 14. Other out-
comes were: average asthma scores as scored
on asthma17 and cough18 diary cards on
Days 5, 10 and 14; recurrence of exacerba-
tion; and unscheduled re-presentation to a
health facility. In accordance with Australian
guidelines,8 we did not use peak flow as an
outcome measure.
Statistical analysis
The sample size required was calculated a
priori from previous data.19 Assuming a
dropout rate of 20%, 180 children (90 per
group) were required for a reduction in
proportion from 60% to 30% of children
known to be symptomatic on Day 7 when
given a longer course of oral corticosteroids.
We recalculated the sample size for the
primary outcomes after the first 30 children
were enrolled, and the sample size increased
to 200 for the same power. For the PACQLQ
outcome, 168 children were required for a
power of 90% at a 5% significance level, for
a minimally important mean difference of
0.5 in PACQLQ scores.20
Data were examined for type of distribu-
tion using normality plots. We used
unpaired Student’s t test for two-group com-
parisons of normally distributed data, the
Kruskal–Wallis test for non-normal data and
Pearson’s χ2 test for categorical variables.
Linear regression was used to examine effect
of asthma severity (ASS)14 on presentation
on Day 7 symptom scores and PACQLQ
scores. A two-tailed P < 0.05 was considered
significant. Data were initially analysed
using intention-to-treat (ITT) analysis, fol-
lowed by per-protocol analysis.
SPSS, version 13.0 (SPSS Inc, Chicago, Ill,
USA) was used for all statistical calculations
except for mean difference between groups
for PACQLQ scores and asthma diary scores,
for which Confidence Interval Analysis
(Gardner M, BMJ, London, UK) was used.
RESULTS
There were 201 children enrolled in the
study: 175 (87%) at Royal Children’s Hospi-
tal, 17 (9%) at Mater Hospital and nine (5%)
1 Flow of participants through the study
3-day group = 3-day course of oral prednisolone plus 2-day course of placebo. 5-day group = 5-day course of 
prednisolone. CS = corticosteroid. ◆
Assessed for eligibility (n = 535)
Enrolment
Excluded (n = 334)
Did not meet inclusion criteria (n = 258)
Refused to participate (n = 76)
Other reasons (n = 0)
Allocated to 3-day group (n = 101)
Received allocated intervention (n = 101)
Did not receive allocated intervention (n = 0)
Allocated to 5-day group (n = 100)
Received allocated intervention (n = 100)
Did not receive allocated intervention (n = 0)
Lost to follow-up or incomplete data
(n = 21)
• Additional oral CS given (n = 2)
• Hospitalised (n = 3)
• Unable to contact (n = 3)
• No reason given (n = 6)
• Carer unwell/busy (n = 2) 
• Medication spat (n = 5)
Lost to follow-up or incomplete data
(n = 15)
• Additional oral CS given (n = 0)
• Hospitalised (n = 3)
• Unable to contact (n = 1)
• No reason given (n = 7)
• Carer unwell/busy (n = 2) 
• Medication spat (n = 2)
Analysed for primary outcome (intention-
to-treat analysis) (n = 101) 
Excluded from secondary analysis (n = 21)
Reason: No comparative data for endpoint
Analysed for primary outcome (intention-
to-treat analysis) (n = 100) 
Excluded from secondary analysis (n = 15)
Reason: No comparative data for endpoint
Allocation
Follow-up
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study (Box 1). Baseline characteristics were
similar for patients in both groups and for
those who completed and did not complete
the study (Box 2). The reasons for dropping
out for 21 children from the 3-day group
and 15 from the 5-day group (P = 0.36) were
also similar (Box 1).
There were five recorded adverse events,
with no significant difference between
groups. In the 3-day group, two parents
reported that their child had behavioural
disturbance (cranky and irritable) and one
had a rash, while two children in the 5-day
group had behavioural disturbance (angry
and aggressive).
Sixty-six children (3-day group, 31; 5-day
group, 35) were symptom-free by Day 7.
ITT analysis showed no significant differ-
ence between groups (observed difference,
0.04 [95% CI, − 0.09 to 0.18]). Per-protocol
analysis showed no significant difference
between groups on Day 7 (observed differ-
ence, 0.04 [95% CI, − 0.17 to 0.09]) or on
Day 4 (0.004 [95% CI, − 0.13 to 0.14]).
PACQLQ scores were obtained for 165
children (82%). The median PACQLQ score
on Day 7 in the 3-day group (5.9; interquar-
tile range [IQR], 1.6) was similar to that of
the 5-day group (5.9; IQR, 1.2) (P = 0.42).
The mean difference between groups
in PACQLQ on Day 7 was 0.18 (95%
CI, − 0.16 to 0.51); on Day 14 it was 0.17
(95% CI, − 0.08 to 0.44).
There was no significant difference
between groups in any other secondary out-
come, with P values ranging from 0.17 to
0.91 (Box 3). The difference between groups
in Day 5 asthma score was 0.02 (95% CI,
− 0.36 to 0.40). Between Days 4 and 14, only
one child (from the 3-day group) was hospi-
talised, and 13 received additional pred-
nisolone (eight children from the 3-day
group; five from the 5-day group). However,
the difference between groups was not sig-
nificant (P = 0.40).
When we categorised children according
to ASS score at presentation, there was also
no difference between groups in any of the
outcomes (data not shown, P values from
0.15 to 0.80). Using linear regression, Day 7
symptom score was not influenced by ASS
category or PACQLQ scores on Day 7 or 14
(P= 0.50, 0.80, and 0.66, respectively).
DISCUSSION
In this multicentre randomised placebo-
controlled trial of children presenting to
EDs (but not hospitalised) for an acute
asthma exacerbation, we found that
asthma morbidity (defined by proportion
of children who were symptom-free at
Day 7, and QOL) was similar whether a 5-
or 3-day course of prednisolone was
given. Two weeks later, there was no
difference in symptoms or QOL between
the groups.
2 Baseline characteristics of the children, by trial group and completion of study 
Data are mean (SD) unless otherwise stated.
3-day group = 3-day course of oral prednisolone plus 2-day course of placebo. 5-day group = 5-day course of 
prednisolone. ETS = environmental tobacco smoke, defined as presence of any smoker in the household. 
PACQLQ = Paediatric Asthma Caregiver’s Quality of Life Questionnaire. CS = corticosteroid. Regular 
medications = child on regular maintenance medications for asthma.
* Comparison of children randomly allocated to receive either 3 or 5 days of prednisolone. 
† Complete = children who completed study (ie, secondary outcomes available). 
‡ Comparison of children who completed and did not complete trial. ◆
3-day group 
(n = 101)
5-day group 
(n = 100) P*
Complete† 
(n = 165)
Incomplete 
(n = 36) P‡
Age in years 4.8 (2.8) 4.7 (3.1) 0.64 4.6 (2.9) 4.1 (3.2) 0.42
Sex (F : M) 40 : 61 40 : 60 0.95 67 : 98 13 : 23 0.38
ETS exposure, no. (%) 34 (34%) 37 (37%) 0.77 57 (35%) 14 (39%) 0.70
Asthma Severity Scale14 4.6 (1.8) 4.5 (1.8) 0.92 5.0 (2.0) 4.5 (1.8) 0.14
Australasian Triage Scale15 2.8 (0.6) 2.9 (0.6) 0.37 2.8 (0.5) 2.9 (0.6) 0.77
PACQLQ16 5.0 (1.0) 5.1 (1.0) 0.99 5.0 (1.1) 5.1 (0.8) 0.92
Inhaled CS, no. (%) 25 (25%) 22 (22%) 0.77 39 (24%) 8 (22%) 0.43
Regular medications, no. (%) 34 (34%) 31 (31%) 0.69 54 (33%) 11 (31%) 0.80
Days unwell 2.5 (1.8) 2.7 (2.4) 0.95 2.7 (2.2) 2.1 (1.2) 0.15
No. of oral CS courses in 
previous 12 months
1.5 (1.7) 1.4 (1.9) 0.42 1.5 (1.8) 1.3 (1.6) 0.42
3 Median scores of asthma-related morbidity in children who received a 5-day or a 3-day course of oral prednisolone
3-day group = 3-day course of oral prednisolone plus 2-day course of placebo. 5-day group = 5-day course of prednisolone. PACQLQ = Paediatric Asthma Caregiver’s 
Quality of Life Questionnaire.16 ◆
0
0 5 10 15 0 5 10 15 0 7 14
0.5
1.0
1.5
2.0
2.5
3.0
3.5
M
ed
ia
n
A: Median of average asthma score
Days from enrolment Days from enrolment
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
M
ed
ia
n
B: Median cough score
0
1
2
3
4
5
6
7
M
ed
ia
n
C: Median PACQLQ score
Days from enrolment
5-day group
3-day group
5-day group
3-day group
5-day group
3-day group308 MJA • Volume 189 Number 6 • 15 September 2008
RESEARCHOur results are similar to those of smaller
single-centre studies, which found that a
shorter duration of systemic corticosteroids
was as effective as a longer course.21,22 In
one study of young children (mean age, 36–
37 months), the short-term morbidity (at
Day 5) of 15 children who received a single
dose of intramuscular dexamethasone was
similar to that of 17 who received oral
prednisolone for 5 days.21 However, some of
these children may not have had asthma.21
In a study of 117 children aged 2–6 years,
outcomes on Day 5 were similar in those
given a single dose of oral dexamethasone
and those given prednisolone twice daily for
5 days.22 Dexamethasone is thought to be
effective for up to 72 hours,22 which
amounts to a similar length of effect to 3
days of prednisolone. We used prednisolone
rather than dexamethasone, as the latter is
only available in hospitals and our findings
would be relevant to children presenting to
general practitioners with acute asthma not
severe enough to require hospitalisation.
However, these studies were arguably
underpowered and did not examine the
effect beyond the first 3–5 days.
Our study was larger and longer, and
included symptom diaries and QOL meas-
ures. The importance of QOL for children
with asthma has been previously high-
lighted,23 and outcomes beyond the period
of corticosteroid administration are impor-
tant, as studies have shown that morbidity
beyond the immediate asthma exacerbation
period is greater than expected.3 Our study
thus adds important high-level evidence to
the literature.
The dose of oral corticosteroids we used
was similar to current guidelines, but lower
than that used in previous studies.21,22 It
was chosen based on current practice and
evidence of adverse events when 2 mg/kg/
day was used.13 Further, a systematic review
found only two trials that assessed clinical
responses to different doses of systemic cor-
ticosteroids; neither found a therapeutic
advantage of higher doses.11
Our study must be interpreted in consid-
eration of its limitations. Although an inade-
quate sample size may have contributed to
our finding of no difference between a 5-day
and 3-day course, we believe this is unlikely,
as the power of our study was 90%. It would
have been ideal to define a non-inferiority or
equivalence margin a priori on the basis of a
minimally important effect or historical con-
trols. Our study was designed as a superior-
ity trial, and we did not define a non-
inferiority margin a priori. Nevertheless, for
the primary outcome measure, the chosen
symptom score cut-off of 0.20 (ie, chosen
minimally important difference), the study
shows equivalence (the upper 95% confi-
dence limit of the difference between groups
in our study was 0.18).
There was also no significant difference
between groups when per-protocol analysis
was performed (as opposed to ITT analysis).
The small difference between groups in
PACQLQ scores on Days 7 and 14 (0.18 and
0.17) was less than the established mini-
mally important mean difference of 0.50 in
PACQLQ scores.20 However, the upper 95%
confidence limit for Day 7 PACQLQ scores
(0.51) is just larger than the minimum
clinically important difference, so equiva-
lence was not shown for this outcome. The
upper 95% confidence limit for PACQLQ on
Day 14 was 0.44, demonstrating equiva-
lence. Also, the difference between groups in
the Day 5 asthma diary score of 0.02 is well
within the non-inferiority margin of
expected change in the diary score17 based
on historical controls. Post-priori calculation
showed that a study size of 201 patients is
sufficient to be 87% sure that the upper 95%
confidence limit for the difference between
the two treatment groups is < 20% for symp-
tom score on Day 4. For PACQLQ scores on
Day 7, 160 children provided 99% surety
that the upper 95% confidence limit for the
difference between the two groups was
< 0.50.
Although our study was a multicentre
study, the different size of the hospitals and
starting dates resulted in unequal distribu-
tion of the children enrolled. Another limita-
tion of our study was the deviation from
protocol. We had intended to include data
to Day 28, as we had done in our previous
study,19 but as many parents found this too
difficult, our data were limited to 14 days.
Nevertheless, given the negative results and
the short duration of action of prednisolone,
it is likely that data beyond 14 days would
not have altered our findings.
Our findings are limited to children who
did not require hospitalisation. We chose
this criterion as this is a more common
problem than hospitalisation and hence
more relevant to the community.
Our study was unique in using patient-
oriented outcomes, which are arguably as
important as objective measures23 — espe-
cially in young children, in whom objective
respiratory measures are limited. We also
examined data beyond the immediate
exacerbation period.
We conclude that a 5-day course of oral
prednisolone confers no additional advan-
tage over a 3-day course for children with an
acute asthma exacerbation that does not
require hospitalisation. Although we saw
few adverse events in our study,  more
significant adverse events following short
courses of oral corticosteroids may
occur.12,13 Shortening courses of oral corti-
costeroids to the minimum effective length
would limit the exposure of children to
unnecessary medications and reduce costs.
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